All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – Israeli biotech firm Atox Bio Inc., of Ness Ziona, is moving ahead with its lead product, reltecimod (AB-103), with two clinical trials ongoing in parallel in the U.S. The funds from the financing round last December will help speed up the development of the drug candidate, pushing it closer to approval in two year's time.